BMJ: SGLT2 inhibitors reduce the risk of cardiovascular events in people with type 2 diabetes.

Recently, researchers examined the effects of sodium glucose co-transport protein 2 (SGLT2) inhibitors and dptide-based peptidease-4 (DPP-4) inhibitors on cardiovascular event risk in patients with type 2 diabetes.
researchers looked at data from the Canadian Observational Drug Effects Research Network (CNODES) database for 2013-18, with 209867 patients treated with SGLT2 inhibitors and 209,867 patients treated with DEP-4 inhibitors, with an average follow-up of 0.9 years.
results of this study were major cardiovascular adverse events (MACE, including myocardial infarction, isoemia stroke, or cardiovascular death).
secondary results were MACE, heart failure and all-cause mortality.
compared to DPP-4 inhibitor users, SGLT2 inhibitors used MACE (incidence per 1000 people-years: 11.4 v 16.5; risk ratio 0.76), myocardial infarction (5.1 vs 6.4; 0. 82), reduced risk of cardiovascular death (3.9 vs. 7.7; 0.60), heart failure (3.1 vs. 7.7; 0.43) and all-cause death (8.7 vs. 17.3; 0.60).
SGLT2 inhibitors had no significant effect on the reduced risk of ischemic stroke in diabetic patients (2.6 v 3.5; 0.85).
similar effects on MACE for Kaglia Net (0.79), Dagly Net (0.73) and Ipale Net (0.77).
study concluded that the risk of cardiovascular events was further reduced when diabetics received SGLT2 inhibitors compared to DEP-4 inhibitors.
.